A versatile nanovaccine platform is based on a synthetic nanoparticle that not only acts as an antigen carrier but also stimulates the STING pathway.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Synergistic combination therapy using cowpea mosaic virus intratumoral immunotherapy and Lag-3 checkpoint blockade
Cancer Immunology, Immunotherapy Open Access 13 February 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Luo, M. et al. Nat. Nanotech. 12, 648–654 (2017).
Siddiqui, M. et al. BioDrugs 5, 313–316 (2006).
Cubillos-Ruiz, J. R. et al. J. Clin. Invest. 119, 2231–2244 (2009).
Lizotte, P. H. et al. Nat. Nanotech. 11, 295–303 (2016).
Ishikawa, H. et al. Nature 455, 674–678 (2008).
Corrales, L. et al. J. Clin. Invest. 126, 2404–2411 (2016).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fiering, S. Making allies of phagocytes. Nature Nanotech 12, 615–616 (2017). https://doi.org/10.1038/nnano.2017.89
Published:
Issue Date:
DOI: https://doi.org/10.1038/nnano.2017.89
This article is cited by
-
Synergistic combination therapy using cowpea mosaic virus intratumoral immunotherapy and Lag-3 checkpoint blockade
Cancer Immunology, Immunotherapy (2024)